CARSgen Therapeutics-B (02171.HK) Rises Nearly 4% on Clinical Collaboration with Dispatch Bio to Evaluate Zevor-cel in Solid Tumors

According to the Zhisheng Finance APP, Dispatch Biotherapeutics-B (02171) rose nearly 4%. As of the time of writing, it increased by 3.96%, trading at HK$16.27, with a turnover of HK$4.9417 million.

In terms of news,Recently,According to the official WeChat account of Tech Pharma, the company announced a clinical collaboration with Dispatch Bio (a biotechnology company leveraging its first-of-its-kind Flare platform to develop universal treatments for solid tumors). The plan is to initiate a Phase I clinical trial in China by 2026. The trial will evaluate the application of the combination therapy DISP-11 in patients with solid tumors.

According to the introduction, the combination therapy includes Dispatch Bio's Flare platform-developed investigational therapies (including its novel tumor-specific virus DV-10) and CARsgen Therapeutics' BCMA-targeted autologous CAR-T cell product, ZeCarT.^®(Zevorkio Injection) in combination. Saikaze® has been approved by the National Medical Products Administration (NMPA) of China for the treatment of multiple myeloma.